SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

ALDURAZYME

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2003.
Why 3/10
No hard, dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for ALDURAZYME in the next 12 months. It is an already-approved, commercialized drug. Per the rubric, an approved drug with no pending regulatory decision scores 3-5. At roughly 6.5% of BioMarin's total revenue, it is a modest contributor to a diversified portfolio, supporting the lower end of that range.
Actionable Insight NEUTRAL

ALDURAZYME has no upcoming PDUFA dates, pivotal readouts, or regulatory decisions. The next meaningful data point for this drug is routine quarterly revenue disclosures within BioMarin's earnings reports. For BioMarin stock, the far larger value drivers are VOXZOGO (achondroplasia) and the recently acquired Amicus Therapeutics portfolio. ALDURAZYME is not a catalyst for BMRN shares.

Price Chart

Loading chart...

Executive Summary

ALDURAZYME (laronidase) is a mature, FDA-approved enzyme replacement therapy for the rare genetic disorder mucopolysaccharidosis I (MPS I). Approved in 2003, it was BioMarin's first drug and is manufactured by BioMarin but marketed globally through a 50/50 joint venture with Sanofi/Genzyme. With 2025 revenue of $208.5 million (roughly 6.5% of BioMarin's $3.2 billion total revenue), it is a steady but modest contributor to a much larger and more diversified portfolio now led by VOXZOGO. There are no upcoming binary catalysts for this drug, and no approved U.S. biosimilars, though a biosimilar candidate from Iran's CinnaGen has been studied. The drug faces long-term pipeline pressure from gene therapies in development.

How It Works

ALDURAZYME is an enzyme replacement therapy. Patients with MPS I are born with a genetic deficiency of the enzyme alpha-L-iduronidase, which normally breaks down certain sugar molecules (glycosaminoglycans) in cells. Without it, these sugars accumulate and cause organ damage. ALDURAZYME provides a synthetic version of the missing enzyme via weekly intravenous infusion, helping clear the accumulated sugars.

Trial Status

ALDURAZYME was approved by the FDA on April 30, 2003, based on a pivotal placebo-controlled Phase 3 study in 45 MPS I patients that showed improvements in pulmonary function and walking distance. It has been commercially available for over 23 years. A biosimilar version (CinnaGen) has completed a Phase 3 crossover study versus Aldurazyme, but no U.S. biosimilar has been approved.

The Two-Sided Case

▲ Bull Case4
ALDURAZYME generated $208.5 million in revenue in 2025, up 13.4% year-over-year, showing steady growth in a well-established rare-disease market.
No approved U.S. biosimilar exists, and manufacturing complexity plus the small patient population create a high barrier to generic competition.
The drug treats a severe, life-limiting genetic disease with no alternative approved enzyme replacement therapy, providing a stable, recurring revenue stream.
BioMarin manufactures the drug, and Sanofi/Genzyme handles global marketing and sales through a 50/50 joint venture, limiting BioMarin's direct commercial expense.
▼ Bear Case5
ALDURAZYME represents only about 6.5% of BioMarin's total revenue ($208.5M of $3.2B in 2025), making it a minor contributor with limited impact on the stock.
U.S. orphan-drug exclusivity expired in 2010, leaving the drug protected only by manufacturing complexity and biologic product profile, not regulatory barriers.
A biosimilar from Iran's CinnaGen has completed a Phase 3 crossover study, signaling eventual biosimilar competition that could erode pricing.
Gene therapies for MPS I from Pfizer and Sangamo Therapeutics are in development and could eventually displace enzyme replacement therapy.
Revenue can be lumpy due to timing of orders from Sanofi, as seen in Q2 2026 when sales volume was down due to order-fulfillment timing.

Upcoming Catalysts

  • None scheduled for this specific drug. ALDURAZYME is a mature marketed product with no pending regulatory decisions or pivotal trial readouts.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 12

Hover a chip for the title
1 accessdata.fda.gov2 accessdata.fda.gov3 biomarin.com4 biomarin.com5 fiscal.ai6 biomarin.com7 biomarin.com8 nature.com9 drugpatentwatch.com10 drugpatentwatch.com11 aldurazyme.com12 purplebooksearch.fda.gov